Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, Cytimmune Sciences is raising $3,000,000.00 in new funding. Sources indicate as part of senior management Founder, Lawrence Tamarkin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytimmune Sciences

Fighting for a more effective, less toxic treatment for cancer patients. CytImmune is a global leader in the field of cancer nanomedicine. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada. We have successfully completed a Phase I clinical trial of CYT-6091 the first in a series of nanomedicines based on our Aurimune nanomedicine platform.

To learn more about Cytimmune Sciences, visit http://www.cytimmune.com/

Contact:
Lawrence Tamarkin, Founder
301-825-3041
ltamarkin@cytimmune.com
https://www.linkedin.com/in/lawrence-tamarkin-387a574a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved